Viatris Inc. (VTRS) BofA Securities 2025 Healthcare Conference (Transcript)

Viatris Inc. (NASDAQ:VTRS) BofA Securities 2025 Healthcare Conference May 13, 2025 8:00 PM ET

Company Participants

Doretta Mistras – CFO
Philippe Martin – Chief R&D Officer

Conference Call Participants

Jason Gerberry – BofA Securities

Jason Gerberry

Keep going here at the BofA Annual Healthcare Conference, and our last company presenter of the day, Viatris. Joining us is Doretta Mistras, Chief Financial Officer; and Philippe Martin, Chief R&D Officer. Martin or Martin?

Philippe Martin

Whatever you want. Martin is good.

Jason Gerberry

Well, thanks. And my name is Jason Gerberry. I cover SMID cap biotech and specialty pharma at BofA.

Question-and-Answer Session

Q – Jason Gerberry

And maybe just for starters, since the Upjohn-Mylan merger and then subsequent some divestitures within the portfolio, if you could just kind of level set in terms of where you are, in terms of setting the strategic compass for the company, what Viatris wants to become as we think to the next 3 to 5 years for the business. I know you guys have been vocal about moving up the value chain in terms of more durable high-growth brands and where you feel like you’re at in terms of that trajectory.

Doretta Mistras

Yes. Thank you, and thank you for having us. We’re happy to be here. As you mentioned, I mean, since the inception of Viatris as we know it today, we’ve integrated 2 very large organizations between Mylan and Upjohn. We’ve also been focused on really streamlining the enterprise over the past couple of years. We’ve made several large divestments, including biosimilars, OTC, women’s health and API.

And kind of today, as we look at portfolio of kind of assets that we have today, we’re really focused on executing on our strategy. That includes delivering on kind of our diverse base business of assets and really